These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 10490967)

  • 1. Tumor gangliosides inhibit the tumor-specific immune response.
    McKallip R; Li R; Ladisch S
    J Immunol; 1999 Oct; 163(7):3718-26. PubMed ID: 10490967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Il-4 is an endogenous T cell growth factor during the immune response to a syngeneic retrovirus-induced tumor.
    Kern DE; Peace DJ; Klarnet JP; Cheever MA; Greenberg PD
    J Immunol; 1988 Oct; 141(8):2824-30. PubMed ID: 2459230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human tumor gangliosides inhibit murine immune responses in vivo.
    Li R; Villacreses N; Ladisch S
    Cancer Res; 1995 Jan; 55(2):211-4. PubMed ID: 7812945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Induction of potent antitumor immune response of leukemia antigen-pulsed dendritic cells by IL-2 gene modification].
    Tang H; Cao X; Zhu X
    Zhonghua Xue Ye Xue Za Zhi; 1999 Nov; 20(11):573-6. PubMed ID: 11721373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ cells: cytolytic T cells can mediate eradication of disseminated leukemia.
    Greenberg PD
    J Immunol; 1986 Mar; 136(5):1917-22. PubMed ID: 3485134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.
    Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T
    Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of long-term T-lymphoid cell lines with specific cytotoxic reactivity for a syngeneic murine lymphoma.
    Eberlein TJ; Rosenstein M; Spiess PJ; Rosenberg SA
    J Natl Cancer Inst; 1982 Jul; 69(1):109-16. PubMed ID: 6980314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shedding and immunoregulatory activity of YAC-1 lymphoma cell gangliosides.
    Ladisch S; Gillard B; Wong C; Ulsh L
    Cancer Res; 1983 Aug; 43(8):3808-13. PubMed ID: 6861145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunoregulatory effects of gangliosides involve immune deviation favoring type-2 T cell responses.
    Crespo FA; Sun X; Cripps JG; Fernandez-Botran R
    J Leukoc Biol; 2006 Mar; 79(3):586-95. PubMed ID: 16415169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of the in vitro secondary cell-mediated cytotoxic response against syngeneic FBL-3 leukemia by macrophages.
    Igarashi T; Teranishi T; Rodrigues D; Yamamura Y
    Microbiol Immunol; 1980; 24(6):599-72. PubMed ID: 6968022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function.
    Shurin GV; Shurin MR; Bykovskaia S; Shogan J; Lotze MT; Barksdale EM
    Cancer Res; 2001 Jan; 61(1):363-9. PubMed ID: 11196188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of suppressed natural killer cell activity with altered host resistance models in B6C3F1 mice.
    Wilson SD; McCay JA; Butterworth LF; Munson AE; White KL
    Toxicol Appl Pharmacol; 2001 Dec; 177(3):208-18. PubMed ID: 11749120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
    Merritt RE; Yamada RE; Crystal RG; Korst RJ
    J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of transforming growth factor-beta-mediated immunosuppression in tumor-draining lymph nodes augments antitumor responses by various immunologic cell types.
    Fujita T; Teramoto K; Ozaki Y; Hanaoka J; Tezuka N; Itoh Y; Asai T; Fujino S; Kontani K; Ogasawara K
    Cancer Res; 2009 Jun; 69(12):5142-50. PubMed ID: 19491278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern.
    Li Q; Carr AL; Donald EJ; Skitzki JJ; Okuyama R; Stoolman LM; Chang AE
    Cancer Res; 2005 Feb; 65(3):1063-70. PubMed ID: 15705908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppression by YAC-1 lymphoma: role of shed gangliosides.
    Lu P; Sharom FJ
    Cell Immunol; 1996 Oct; 173(1):22-32. PubMed ID: 8871598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ganglioside inhibition of CD8+ T cell cytotoxicity: interference with lytic granule trafficking and exocytosis.
    Lee HC; Wondimu A; Liu Y; Ma JS; Radoja S; Ladisch S
    J Immunol; 2012 Oct; 189(7):3521-7. PubMed ID: 22956583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GD2 ganglioside-specific monoclonal antibody reacts with murine cytotoxic T lymphocytes reactive with FBL-3N erythroleukaemia.
    Yoshimura A; Takamiya K; Kato I; Nakayama E; Shiku H; Furukawa K
    Scand J Immunol; 1994 Nov; 40(5):557-63. PubMed ID: 7973461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.